Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.66 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.66 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.66 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.66 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.66 |
| ▸ | SCN1A | P35498 | 1/20 | 0.66 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.66 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.66 |
| ▸ | DRD2 | P14416 | 6/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18282585 | 1.00 | HTR1A (0.67) | HTR1ASIGMAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL11854599 | 0.87 | ADRA2A (0.84) | HTR1ASIGMAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL16117808 | 0.86 | ADRA2A (0.61) | HTR1ASIGMAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL13150060 | 0.83 | HTR1A (0.63) | HTR1ASIGMAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL8131179 | 0.83 | HTR1A (0.65) | HTR1ASIGMAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL11214812 | 0.83 | ADRA2A (0.64) | HTR1ASIGMAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL20423955 | 0.82 | ADRA2A (0.57) | HTR1ASIGMAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL20423956 | 0.82 | ADRA2A (0.57) | HTR1ASIGMAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL2454473 | 0.81 | ADRA2A (0.63) | HTR1ASIGMAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL14454754 | 0.81 | ADRA2A (0.97) | HTR1ASIGMAR1ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612061-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-11-03 | — | — | US | disclosed |
| US-20090076030-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | disclosed |
| US-20090075982-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | disclosed |
| US-7465733-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2008-12-16 | — | — | US | disclosed |
| EP-1710240-B1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | SERVIER LAB (FR) | 2007-12-05 | — | — | EP | disclosed |
| US-20060229318-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-12 | — | — | US | disclosed |
| EP-1710240-A1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | Les Laboratoires Servier (FR) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075982-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | HTR1A 26/4885SIGMAR1 64/4885ADRA2A 9/4885 |
| US-20090076030-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | HTR1A 26/4885SIGMAR1 64/4885ADRA2A 9/4885 |
| US-20060229318-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | HTR1A 26/4885SIGMAR1 64/4885ADRA2A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.